AFM
FRTX

Anson Funds Management’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Anson Funds Management’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-29,648
Closed -$1.04M – 320
2020
Q4 		$1.04M Buy
+29,648
New +$931K 0.21% 106

Other funds holding FRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Anson Funds Management's FRTX Position: Q1 2021 in Review

Anson Funds Management sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q1 2021, closing a stake of 29,648 shares — an estimated $1.04M sold.

Anson Funds Management first reported a position in FRTX in Q4 2020 and held it in 1 quarter. The position peaked at $1.04M in Q4 2020. 27 funds tracked by Wall St. Rank hold FRTX as of Q1 2021.

  • Anson Funds Management reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Anson Funds Management sold 29,648 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.04M.
  • Anson Funds Management first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Anson Funds Management's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $1.04M in Q4 2020.
  • 27 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Anson Funds Management's 13F filing for Q1 2021, filed 14 May 2021.